Smart Investing Blog2023-08-31T12:12:29+00:00
2406, 2024

THE PRESIDENTIAL ELECTION CYCLE AND THE FED

By |June 24th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Market in Review, Stock Market News, VectorVest|Tags: , , , , , , , |

Written by: Angela Akers As they have done for the last year, the Federal Reserve moved last week to leave interest rates unchanged at the elevated rate of 5.25% – 5.50% and signaled only one cut this year. That same morning, the May Consumer Price Index was released, coming in at a lower-than-expected increase of 3.3%. Additionally, Q1 earnings [...]

2306, 2024

Top 10 Monthly Dividend Stocks to Hold Forever

By |June 23rd, 2024|Categories: Stock Market|Tags: , |

Investing in monthly dividend stocks is a great way to earn consistent income to cover ongoing expenses. Or, you could be trying to invest for early retirement hoping to harness the compounding returns dividend stocks have to offer. Whatever the case, you’ve come to the right place. We’re going to unveil the top 10 monthly dividend stocks to hold forever [...]

2206, 2024

Pros and Cons of Dividend Stocks

By |June 22nd, 2024|Categories: Stock Market|Tags: , |

Dividend stocks are one of the top stock investment strategies as they can provide supplemental income for present-day expenses OR be used to build towards long-term wealth goals through a reinvestment strategy.  No matter your goals with investing in dividend stocks, you’re typically going to enjoy much less volatility. We consider blue chip stocks with dividends to be among the [...]

2106, 2024

Sarepta Shoots up 36% on New Drug Breakthrough for DMD: 2 Reasons to Consider Buying SRPT

By |June 21st, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , |

Sarepta Therapeutics (SRPT) announced late Thursday it had gained FDA approval for its treatment designed to target a rare genetic disease known as Duchenne muscular dystrophy (DMD). This condition causes progressive weakness, predominantly in boys, and is caused by a lack of key protein dystrophin. It has no known cure at this time. The typical protocol includes physical therapy [...]

2006, 2024

Accenture Jumps 7% on Upbeat Forecast Despite Earnings Miss: Does AI Growth Make ACN a BUY?

By |June 20th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

Accenture (ACN) delivered fiscal Q3 results Thursday morning right before the market opened, and despite a miss on the top and bottom lines, the company’s forecast for the road ahead was enough to send shares nearly 7% higher. Revenue for the third quarter was disappointing at just $16.47 billion, narrowly below the $16.53 billion estimate. Adjusted profit per share [...]

1906, 2024

Dell Was Down After Disappointing Earnings, But the Road to Recovery is Underway: Time to Buy?

By |June 19th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

Just last month Dell Technologies (DELL) reported first-quarter earnings that fell short of Wall Street’s expectations, taking the stock down from its all-time high of $179/share. It fell more than 30% in just a few days, eroding market cap and scaring investors out of their positions.  The issue was that despite AI growth fueling the top and bottom lines, [...]

Analyze Any Stock Free

30-DAY TRIAL

  • FREE MOBILE APP
  • FREE COACHING
  • FREE QUICK START COURSE
Ready to test-drive VectorVest? Sign up now and
try a simpler approach to picking the right stocks.
Go to Top